GLP-1 & incretin receptor agonists
Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists.
How this class works
Agonism at the GLP-1 receptor (and, for newer agents, GIP and/or glucagon receptors) enhances glucose-dependent insulin release, slows gastric emptying, and reduces appetite via central pathways.
Semaglutide grades highest (S-tier) on current published evidence; approved members: Semaglutide, Liraglutide, Tirzepatide. This reflects evidence maturity — not a recommendation to use anything.
Compounds in this class
Head-to-head: Semaglutide vs Liraglutide
FAQ
Which glp-1 & incretin receptor agonists has the strongest evidence?
Semaglutide currently grades highest in this class (S-tier) on published evidence — which reflects evidence maturity, not a recommendation.
Are any glp-1 & incretin receptor agonists FDA-approved?
Yes — Semaglutide, Liraglutide, Tirzepatide are FDA-approved for specific indications. Others in the class are investigational or research-only.
How do compounds in this class differ?
Agonism at the GLP-1 receptor (and, for newer agents, GIP and/or glucagon receptors) enhances glucose-dependent insulin release, slows gastric emptying, and reduces appetite via central pathways. Within the class, members differ widely in evidence maturity, approval status, and safety — the tiers and evidence stages above show how.
Research reference only. Not medical advice. Compounds in a class can differ greatly in evidence, approval status, and safety.